Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Insurance
    • ICICI Lombard...

    ICICI Lombard frontrunner for Star Health

    Written by Ruby Khatun Khatun Published On 2018-04-18T10:15:38+05:30  |  Updated On 18 April 2018 10:15 AM IST
    ICICI Lombard frontrunner for Star Health

    Mumbai: In a race to acquire Star Health, ICICI Lombard General Insurance Co has emerged as the leader edging past the competing consortium of West Bridge Capital and Rakesh Jhunjhunwala, valuing the company at Rs 6,000 crores, according to a recent report in ET.


    V Jagannathan, former CMD of United India is the man behind the firm who has driven the company to become one of the profitable insurers in the health space, who holds a 3.5% stake in the company.


    The firm is owned by global and local VCs and private equity funds led by Sequoia Capital-owned Snowdrop Capital Pte Ltd, Oman-based insurer Oman Insurance Company and Dubai-based conglomerate ETA Trading and other investors in its operating company include ICICI Venture, Tata Capital Ltd, Apis Partners LLP and Alpha TC Holdings Pte Ltd among others.


    Currently, Star Health’s promoter group holds close to 44 percent, of which 37.5 percent is with domestic investors and 6.16 percent is with foreign investors. Total foreign investment in the company stood at 36.5 percent as against the maximum permissible 49 percent.


    According to the daily, the value of the company has raised after the last round of investment. Apis Partners and ICICI Venture purchased a 15 percent stake for Rs 320 crores at a valuation of more than Rs 2,100 crores.


    Warburg Pincus is a key investor in ICICI Lombard and if the deal become successful, ICICI Lombard will become the leading player in the health insurance segment in the country.


    An official told ET, “There were various combinations that were being considered — a transaction at the holding company or at the operating company, keeping in mind the tax implications. The incumbent management is backing a financial bidder but ICICI Lombard has the edge.”


    Speraking with ET, another source said, “However, the second-highest bidder might also be asked to revise the terms as a fallback option.”


    West Bridge joined with Jhunjhunwala after its earlier partner Kedaara Capital opted out due to valuation differences. The third bidder that was selected for the final rounds of negotiations was UK insurer Prudential Plc along with Premji Invest.


    As per the news report, the transaction will mark the finale of an 18-month bidding process, which saw interest from over a dozen bulge-bracket private equity funds like Bain Capital, Warburg and insurance peers like HDFC Ergo and Hero Fin-Corp and Bajaj Allianz.

    ICICI LombardICICI Lombard General Insurance CoRakesh JhunjhunwalaStar HealthStar Health and Allied insuranceV JagannathanWest Bridge Capital
    Source : with inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok